Laird Norton Wetherby Trust Company LLC Trims Stock Position in Athira Pharma, Inc. $ATHA

Laird Norton Wetherby Trust Company LLC cut its stake in Athira Pharma, Inc. (NASDAQ:ATHA) by 92.1% in the 3rd quarter, Holdings Channel reports. The firm owned 10,088 shares of the company’s stock after selling 117,221 shares during the period. Laird Norton Wetherby Trust Company LLC’s holdings in Athira Pharma were worth $42,000 at the end of the most recent quarter.

Separately, Focus Partners Wealth bought a new stake in shares of Athira Pharma during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Price Performance

Shares of NASDAQ ATHA opened at $7.66 on Tuesday. Athira Pharma, Inc. has a 1 year low of $2.20 and a 1 year high of $8.36. The stock has a market capitalization of $30.21 million, a P/E ratio of -0.79 and a beta of 2.79. The company’s 50-day moving average is $5.72 and its 200 day moving average is $4.94.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.